Platelets circulate in an activated state in inflammatory bowel disease

Collins, Carole; Cahill, Mary R.; Newland, Adrian C.; Rampton, David

doi:10.1016/0016-5085(94)90741-2

Cited by 216 publications

(165 citation statements)

References 38 publications

Supporting

Mentioning

154

Contrasting

Unclassified

Order By: Relevance

“…This is often associated with a reduced platelet lifespan and reduction in mean platelet volume (Webberley et al, 1993;Jaremo and SandbergGertzen, 1996). Furthermore, platelets from inflammatory bowel disease (IBD) patients are more sensitive to platelet agonists in vitro (van Wersch et al, 1990), while the plateletspecific chemokines PF-4 and b-TG are detected in plasma, revealing activation in vivo (Collins et al, 1994;Vrij et al, 2000). A role for platelets in mediating leukocyte recruitment to the inflamed colon is likely since platelet P-selectin and RANTES are also detected (Fagerstam et al, 2000), and this is localized to the intestinal microcirculation (Collins et al, 1997).…”

Section: Platelet Activation In Inflammatory Bowel Diseasementioning

confidence: 99%

Novel uses for anti‐platelet agents as anti‐inflammatory drugs

Pitchford

2007

British J Pharmacology

View full text Add to dashboard Cite

An alteration in the character and function of platelets is manifested in patients with inflammatory diseases, and these alterations have been dissociated from the well‐characterized involvement of platelets in thrombosis and haemostasis. Recent evidence reveals platelet activation is sometimes critical in the development of inflammation. The mechanisms by which platelets participate in inflammation are diverse, and offer numerous opportunities for future drug intervention. There is now acceptance that platelets act as innate inflammatory cells in immune responses, with roles as sentinel cells undergoing surveillance, responding to microbial invasion, orchestrating leukocyte recruitment, and migrating through tissue, causing damage and influencing repair processes in chronic disease. Some of these processes are targeted by drugs that are being developed to target platelet participation in atherosclerosis. The actions of platelets therefore influence the pathogenesis of diverse inflammatory diseases in various body compartments, encompassing parasitic and bacterial infection, allergic inflammation (especially asthma and rhinitis), and non‐atopic inflammatory conditions, for example, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and atherosclerosis. This review will first discuss the evidence for platelet activation in these various inflammatory diseases, and secondly discuss the mechanisms by which this pathogenesis occurs and the various anti‐platelet agents which have been developed to combat platelet activation in atherosclerosis and their potential future use for the treatment of other inflammatory diseases.British Journal of Pharmacology (2007) 152, 987–1002; doi:10.1038/sj.bjp.0707364; published online 2 July 2007

show abstract

Section: Platelet Activation In Inflammatory Bowel Diseasementioning

confidence: 99%

Novel uses for anti‐platelet agents as anti‐inflammatory drugs

Pitchford

2007

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…This interest is grounded on evidence from clinical studies of colon inflammation showing that this disease can trigger several extra-intestinal problems that appear to be associated with a decreased bio-availability of NO, including enhanced platelet aggregation [14][15][16][17] and thromboembolic events [18][19][20][21] .…”

Section: Introductionmentioning

confidence: 99%

On the dynamics of nitrite, nitrate and other biomarkers of nitric oxide production in inflammatory bowel disease

et al. 2010

View full text Add to dashboard Cite

“…We, and others, have recently shown (published so far in abstract form [18,19]) that platelets in patients with IBD circulate in an activated state with expression and release of adhesion molecules, growth modulators and coagulation factors from platelet agranules [16][17][18][19][20]; these effects could contribute to the increased risk of thromboembolic complications seen in IBD. In this study, in vitro, IL-lp and IL-8 enhances platelet activation, as demonstrated by pselectin and GPIIb/IIIa expression suggesting functional platelet IL-1 and IL-8 receptors, moreover, it indicates a direct involvement of cytokines in modulation of platelet function in inflammation.…”

Section: Discussionmentioning

confidence: 99%

“…Abnormal coagulation parameters and platelet function has been reported in IBD, and recent studies suggest Crohn's disease is associated with vasculitis [16][17][18][19][20]. In addition to the well known haemostatic properties of platelets, there is evidence from in vitro studies that through membrane mediated IL-1, activated platelets induce vascular endothelial cells to secrete IL-8 and to express both intercellular adhesion molecule-1 (ICAM-1) as well as the endothelial leucocyte adhesion molecule-1 (ELAM-l), which promote polymorphonuclear leucocyte (PMNL) migration across the endothelium [21,22].…”

Section: Introductionmentioning

confidence: 99%

Platelets in ulcerative colitis and Crohn's disease express functional interleukin‐1 and interleukin‐8 receptors

Schaufelberger

Uhr

McGuckin

et al. 1994

Eur J Clin Investigation

View full text Add to dashboard Cite

Abstract, Tissue and plasma concentrations of several cytokines are increased in patients with inflammatory bowel disease (IBD). Platelets play an important role in inflammation and circulate in an activated state in patients with IBD. This study assesses the expression of IL-8 and IL-1 receptors on the surface of platelets from patients with IBD using phycoerythrin (PE)-labelled recombinant human rhIL-lp and rhIL-8 and flow cytometry. The percentage IL-1R expressing platelets (median and interquartile range IQR) in the IBD group was 8.7% (5.5-18.2) compared to 4.2% (2.3-6.1) in controls (P = 0.02). The percentage IL-8R expressing platelets in the IBD group was 22.5% (16.5-27.9) and 9.2% (4.3-9.6) in controls ( P < 0.001). Furthermore, platelet IL-1R expression in patients with IBD was inversely related to the total daily dose of steroids ( r = -0.71, P < 0.01 linear regression analysis). Finally, platelet rich plasma from healthy controls was stimulated with rhIL-lp and rhIL-8 and assessed for activation dependent expression of platelet aGPIIb/IIIa and CD62 (pselectin, GMP-140). IL-IP and IL-8 in vitro significantly and specifically activated the platelets. The surface membrane of platelets is able to express functional IL-1R and IL-8R, the expression of which is signficantly increased in IBD. Interleukinl p and IL-8 modulate platelet activation in vitro indicating a target role for platelet function in inflammation.

show abstract

Platelets circulate in an activated state in inflammatory bowel disease

Cited by 216 publications

References 38 publications

Novel uses for anti‐platelet agents as anti‐inflammatory drugs

Novel uses for anti‐platelet agents as anti‐inflammatory drugs

On the dynamics of nitrite, nitrate and other biomarkers of nitric oxide production in inflammatory bowel disease

Platelets in ulcerative colitis and Crohn's disease express functional interleukin‐1 and interleukin‐8 receptors

Contact Info

Product

Resources

About